GTC Biotherapeutics (GTC) business strategy is to form business relationships that provide unique benefits to our partners through the economic enablement created by the production of recombinant proteins in the milk of transgenic animals. Transgenic production provides several advantages compared to mammalian cell culture and other more traditional methods of pharmaceutical protein production. These include: competitive cost of goods with respect to price per gram of material, favorable capital expense structure with respect to both the absolute amount of investment required and flexibility of timing of investment and the ability to produce biotherapeutics which cannot be made in a commercially feasible manner in any other system.